<p>贝叶斯资本管理公司在第二季度收购了查尔斯河实验室国际公司（NYSE:CRL - 免费报告）的新头寸，根据该公司在最近向证券交易委员会的披露。该基金收购了 26,602 股这家医疗研究公司的股票，价值约为 4,036,000 美元。贝叶斯资本管理公司在最近的报告期末持有查尔斯河实验室国际公司 0.05% 的股份。</p>
<ul>
<li>今年迄今表现最差的两只标准普尔 500 指数股票：买入、卖出还是回避？</li>
</ul>
<p>其他一些对冲基金最近也买卖了 CRL 的股票。英维斯科有限公司在第二季度将其在查尔斯河实验室国际公司的股份提高了 11.6%。英维斯科有限公司目前拥有 1,237,143 股这家医疗研究公司的股票，价值 187,712,000 美元，此前在该期间又购买了 128,785 股。拉塞尔投资集团有限公司在第二季度将其在查尔斯河实验室国际公司的持股增加了 59.8%。拉塞尔投资集团有限公司目前拥有 31,175 股这家医疗研究公司的股票，价值 4,730,000 美元，此前在上个季度又购买了 11,667 股。加拿大丰业银行在第二季度将其在查尔斯河实验室国际公司的持股增加了 10,860.5%。加拿大丰业银行目前拥有 203,318 股这家医疗研究公司的股票，价值 30,849,000 美元，此前在上个季度又购买了 201,463 股。Balefire LLC 在第二季度将其在查尔斯河实验室国际公司的头寸提高了 39.4%。Balefire LLC 目前拥有 13,494 股这家医疗研究公司的股票，价值 2,047,000 美元，此前在该期间又收购了 3,815 股。最后，第三银行在第二季度将其在查尔斯河实验室国际公司的股份提高了 47.1%。第三银行目前拥有 12,871 股这家医疗研究公司的股票，价值 1,953,000 美元，此前在上个季度又收购了 4,124 股。对冲基金和其他机构投资者持有该公司 98.91% 的股份。</p>
<h2>查尔斯河实验室国际公司股票表现</h2>
<p>CRL 股票周五开盘价为 194.34 美元。该公司的市值为 95.7 亿美元，市盈率为-124.58，PEG 比率为 6.88，贝塔值为 1.63。查尔斯河实验室国际公司的 52 周最低价为 91.86 美元，52 周最高价为 199.66 美元。该公司的速动比率为 1.10，流动比率为 1.37，债务股本比率为 0.64。该公司的 50 日移动平均线为 177.09 美元，200 日移动平均线为 162.91 美元。</p>
<p>查尔斯河实验室国际公司（NYSE:CRL - 获取免费报告）最后一次公布季度财报是在 11 月 5 日，星期三。这家医疗研究公司报告的每股收益（EPS）为 2.43 美元，超过分析师的共识预期 2.32 美元，超出 0.11 美元。该公司本季度的收入为 10 亿美元，而共识预期为 9.9043 亿美元。查尔斯河实验室国际公司的股本回报率为 15.78%，净利润率为-2.07%。该公司的收入较去年同期下降了 0.5%。去年同期，该公司每股收益为 2.59 美元。分析师平均预计查尔斯河实验室国际公司将在当前财政年度发布 9.36 美元的每股收益。</p>
<h2>分析师评级变动</h2>
<p>CRL 最近成为几份研究报告的主题。华尔街禅在 11 月 8 日的报告中将查尔斯河实验室国际公司的评级从 “买入” 下调至 “持有”。TD Cowen 在 11 月 10 日的报告中将查尔斯河实验室国际公司的目标股价从 205.00 美元下调至 197.00 美元，并对该股票给予 “买入” 评级。阿古斯在 11 月 17 日的研究报告中对查尔斯河实验室国际公司设定了 200.00 美元的目标价。罗伯特·W·贝尔德在 11 月 6 日的报告中将查尔斯河实验室国际公司的评级从 “中性” 上调至 “跑赢大盘”，并将该公司的目标股价从 178.00 美元提高至 199.00 美元。最后，瑞穗在 10 月 17 日的研究报告中将查尔斯河实验室国际公司的目标股价从 155.00 美元提高至 174.00 美元，并对该股票给予 “中性” 评级。一位分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，六位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 190.86 美元。</p>
<p><strong>查看我们最新的查尔斯河实验室国际公司股票报告</strong></p>
<h2>查尔斯河实验室国际公司简介</h2>
<p>（免费报告）</p>
<p>查尔斯河实验室国际公司在美国、欧洲、加拿大、亚太地区及国际上提供药物发现、非临床开发和安全测试服务。它通过三个部门运营：研究模型与服务（RMS）、发现与安全评估（DSA）和制造解决方案（Manufacturing）。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过查尔斯河实验室国际公司</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>2026 年需避免的三只最近被下调的股票</li>
<li>工业产品股票投资</li>
<li>芯片热潮回归：三只有巨大收益潜力的股票</li>
<li>动量投资与长期投资的区别</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在查尔斯河实验室吗？</h2>
<p>在你考虑查尔斯河实验室之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而查尔斯河实验室并不在名单上。</p>
<p>虽然查尔斯河实验室目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

查尔斯河

<p>贝叶斯资本管理公司在第二季度收购了 26,602 股查尔斯河实验室国际公司的股票，价值 4,036,000 美元。其他对冲基金也增加了他们的持股。CRL 的股票开盘价为 194.34 美元，市值为 95.7 亿美元。分析师对该股票的共识评级为 “适度买入”，目标价格为 190.86 美元</p>

<p>Bayesian Capital Management LP acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The fund acquired 26,602 shares of the medical research company's stock, valued at approximately $4,036,000. Bayesian Capital Management LP owned 0.05% of Charles River Laboratories International at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>贝叶斯资本管理公司在第二季度收购了查尔斯河实验室国际公司（NYSE:CRL - 免费报告）的新头寸，根据该公司在最近向证券交易委员会的披露。该基金收购了 26,602 股这家医疗研究公司的股票，价值约为 4,036,000 美元。贝叶斯资本管理公司在最近的报告期末持有查尔斯河实验室国际公司 0.05% 的股份。</p>
</div><ul>
<li>The 2 Worst Performing S&amp;P 500 Stocks YTD: Buy, Sell, or Avoid?</li>
</ul>
<div class="lb-trans"><ul>
<li>今年迄今表现最差的两只标准普尔 500 指数股票：买入、卖出还是回避？</li>
</ul>
</div><p>A number of other hedge funds also recently bought and sold shares of CRL. Invesco Ltd. lifted its stake in shares of Charles River Laboratories International by 11.6% in the 2nd quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company's stock worth $187,712,000 after purchasing an additional 128,785 shares during the period. Russell Investments Group Ltd. increased its holdings in Charles River Laboratories International by 59.8% during the second quarter. Russell Investments Group Ltd. now owns 31,175 shares of the medical research company's stock valued at $4,730,000 after buying an additional 11,667 shares during the last quarter. Bank of Nova Scotia increased its holdings in Charles River Laboratories International by 10,860.5% during the second quarter. Bank of Nova Scotia now owns 203,318 shares of the medical research company's stock valued at $30,849,000 after buying an additional 201,463 shares during the last quarter. Balefire LLC raised its position in Charles River Laboratories International by 39.4% in the second quarter. Balefire LLC now owns 13,494 shares of the medical research company's stock worth $2,047,000 after acquiring an additional 3,815 shares during the period. Finally, Fifth Third Bancorp boosted its stake in shares of Charles River Laboratories International by 47.1% during the 2nd quarter. Fifth Third Bancorp now owns 12,871 shares of the medical research company's stock worth $1,953,000 after acquiring an additional 4,124 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.</p>
<div class="lb-trans"><p>其他一些对冲基金最近也买卖了 CRL 的股票。英维斯科有限公司在第二季度将其在查尔斯河实验室国际公司的股份提高了 11.6%。英维斯科有限公司目前拥有 1,237,143 股这家医疗研究公司的股票，价值 187,712,000 美元，此前在该期间又购买了 128,785 股。拉塞尔投资集团有限公司在第二季度将其在查尔斯河实验室国际公司的持股增加了 59.8%。拉塞尔投资集团有限公司目前拥有 31,175 股这家医疗研究公司的股票，价值 4,730,000 美元，此前在上个季度又购买了 11,667 股。加拿大丰业银行在第二季度将其在查尔斯河实验室国际公司的持股增加了 10,860.5%。加拿大丰业银行目前拥有 203,318 股这家医疗研究公司的股票，价值 30,849,000 美元，此前在上个季度又购买了 201,463 股。Balefire LLC 在第二季度将其在查尔斯河实验室国际公司的头寸提高了 39.4%。Balefire LLC 目前拥有 13,494 股这家医疗研究公司的股票，价值 2,047,000 美元，此前在该期间又收购了 3,815 股。最后，第三银行在第二季度将其在查尔斯河实验室国际公司的股份提高了 47.1%。第三银行目前拥有 12,871 股这家医疗研究公司的股票，价值 1,953,000 美元，此前在上个季度又收购了 4,124 股。对冲基金和其他机构投资者持有该公司 98.91% 的股份。</p>
</div><h2>Charles River Laboratories International Stock Performance</h2>
<div class="lb-trans"><h2>查尔斯河实验室国际公司股票表现</h2>
</div><p>Shares of CRL stock opened at $194.34 on Friday. The firm has a market cap of $9.57 billion, a price-to-earnings ratio of -124.58, a PEG ratio of 6.88 and a beta of 1.63. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $199.66. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The company's 50 day moving average is $177.09 and its 200 day moving average is $162.91.</p>
<div class="lb-trans"><p>CRL 股票周五开盘价为 194.34 美元。该公司的市值为 95.7 亿美元，市盈率为-124.58，PEG 比率为 6.88，贝塔值为 1.63。查尔斯河实验室国际公司的 52 周最低价为 91.86 美元，52 周最高价为 199.66 美元。该公司的速动比率为 1.10，流动比率为 1.37，债务股本比率为 0.64。该公司的 50 日移动平均线为 177.09 美元，200 日移动平均线为 162.91 美元。</p>
</div><p>Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business's revenue was down .5% compared to the same quarter last year. During the same period last year, the business posted $2.59 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>查尔斯河实验室国际公司（NYSE:CRL - 获取免费报告）最后一次公布季度财报是在 11 月 5 日，星期三。这家医疗研究公司报告的每股收益（EPS）为 2.43 美元，超过分析师的共识预期 2.32 美元，超出 0.11 美元。该公司本季度的收入为 10 亿美元，而共识预期为 9.9043 亿美元。查尔斯河实验室国际公司的股本回报率为 15.78%，净利润率为-2.07%。该公司的收入较去年同期下降了 0.5%。去年同期，该公司每股收益为 2.59 美元。分析师平均预计查尔斯河实验室国际公司将在当前财政年度发布 9.36 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>CRL has been the subject of several recent research reports. Wall Street Zen lowered Charles River Laboratories International from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. TD Cowen reduced their price target on shares of Charles River Laboratories International from $205.00 to $197.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, November 10th. Argus set a $200.00 price objective on Charles River Laboratories International in a research note on Monday, November 17th. Robert W. Baird raised shares of Charles River Laboratories International from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price target for the company from $178.00 to $199.00 in a report on Thursday, November 6th. Finally, Mizuho raised their price target on Charles River Laboratories International from $155.00 to $174.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $190.86.</p>
<div class="lb-trans"><p>CRL 最近成为几份研究报告的主题。华尔街禅在 11 月 8 日的报告中将查尔斯河实验室国际公司的评级从 “买入” 下调至 “持有”。TD Cowen 在 11 月 10 日的报告中将查尔斯河实验室国际公司的目标股价从 205.00 美元下调至 197.00 美元，并对该股票给予 “买入” 评级。阿古斯在 11 月 17 日的研究报告中对查尔斯河实验室国际公司设定了 200.00 美元的目标价。罗伯特·W·贝尔德在 11 月 6 日的报告中将查尔斯河实验室国际公司的评级从 “中性” 上调至 “跑赢大盘”，并将该公司的目标股价从 178.00 美元提高至 199.00 美元。最后，瑞穗在 10 月 17 日的研究报告中将查尔斯河实验室国际公司的目标股价从 155.00 美元提高至 174.00 美元，并对该股票给予 “中性” 评级。一位分析师对该股票给予了强烈买入评级，十位分析师给予了买入评级，六位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 190.86 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Charles River Laboratories International</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的查尔斯河实验室国际公司股票报告</strong></p>
</div><h2>Charles River Laboratories International Profile</h2>
<div class="lb-trans"><h2>查尔斯河实验室国际公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).</p>
<div class="lb-trans"><p>查尔斯河实验室国际公司在美国、欧洲、加拿大、亚太地区及国际上提供药物发现、非临床开发和安全测试服务。它通过三个部门运营：研究模型与服务（RMS）、发现与安全评估（DSA）和制造解决方案（Manufacturing）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Charles River Laboratories International</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>Industrial Products Stocks Investing</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Differences Between Momentum Investing and Long Term Investing</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过查尔斯河实验室国际公司</li>
<li>如何使用 MarketBeat 股息计算器</li>
<li>2026 年需避免的三只最近被下调的股票</li>
<li>工业产品股票投资</li>
<li>芯片热潮回归：三只有巨大收益潜力的股票</li>
<li>动量投资与长期投资的区别</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNSTA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=CRL"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Charles River Laboratories International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在查尔斯河实验室吗？</h2>
</div><p>Before you consider Charles River Laboratories International, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑查尔斯河实验室之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而查尔斯河实验室并不在名单上。</p>
</div><p>While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然查尔斯河实验室目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

贝叶斯资本管理公司在查尔斯河实验室国际公司持有股份 $CRL